Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Dosing of Ruxolitinib in Myelofibrosis
NCT01445769Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Incyte. Started Sep 2011; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01445769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445769.